Chemotherapy in Treating Patients Who Have Hematologic Cancer

Phase 1 Completed Daiichi Sankyo

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of DX-8951f in treating patients who have hematologic cancer.

Timeline

Start: 1999-06
Primary completion: 2005-04
Completion: 2005-04

Publications

Results Giles FJ, Cortes JE, Thomas DA, Garcia-Manero G, Faderl S, Jeha S, De Jager RL, Kantarjian HM. Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia. Clin Cancer Res. 2002 Jul;8(7):2134-41.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	exatecan	Small molecule	0.6 mg/m2	Intravenous
Subject	exatecan	Small molecule	0.9 mg/m2	Intravenous
Subject	exatecan	Small molecule	1.2 mg/m2	Intravenous
Subject	exatecan	Small molecule	1.35 mg/m2	Intravenous

Chemotherapy in Treating Patients Who Have Hematologic Cancer

Summary

Timeline

Publications

Drugs

Indications